Tuesday, April 21, 2020

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Accomplished Executive Shannon Inman to Drive Launch of Key Clinical Trials


Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment in this new position. These clinical trials include those with Genprex’s lead drug candidate, Oncoprex(TM), for non-small cell lung cancer (“NSCLC”), which recently received Fast Track Designation for its combination with osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug Tagrisso(R). “Genprex continues to strengthen its leadership team with the appointment of an accomplished executive to drive the launch of key clinical trials,” Genprex Chairman and CEO Rodney Varner said in the news release. “Ms. Inman brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small biotechnology companies and top tier academic institutions. She will be instrumental in continuing to build the long-term value of our gene therapies. With the addition of our second investigational gene therapy asset addressing the unmet medical need of people suffering from diabetes, I’m excited about building the necessary infrastructure to facilitate our growth.”

To view the full press release, visit http://ibn.fm/oCfHZ

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html